A confirmatory study of opaganib in the targeted moderately severe hospitalized COVID-19 patient group
Latest Information Update: 13 Dec 2021
At a glance
- Drugs Opaganib (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors RedHill Biopharma
- 13 Dec 2021 New trial record
- 06 Dec 2021 According to a RedHill Biopharma media release, the company is in discussion with regulatory authorities or a confirmatory study with opaganib in the targeted moderately severe hospitalized patient group.